Practice Areas - Corporate and M&A Law Firms and Lawyers
| Deal Date: | 03-03-2020 | Practice Area: | Corporate and M&A |
| Deal Title: | Immunocore Limited Series B Equity Fundraising | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Slaughter and May advised Immunocore Limited on its Series B equity fundraising. The fundraising completed on 2 March 2020 and generated proceeds of more than USD130 million, with both new investors and existing shareholders participating in the fundraising.
Immunocore Limited was a clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. The proceeds of the fundraising enabled Immunocore Limited to further expand and accelerate the development of its technology.
|
||
| Financial Center: | London | Value: | 100.01-500.00 |
| Advised Party: | Investee | Law Firm | Slaughter and May |
| Investee 1 Jurisdiction | United Kingdom | Investee 2 Jurisdiction | United Kingdom |
| Classification: |
Venture and Growth Capital Healthcare |
Lawyer | Jeff Twentyman |
